Walleye Capital LLC has recently announced that it has increased stake in Bone Biologics Corp (NASDAQ:BBLG) by 997.80%. After grabbing 0.29 million shares, the institutional investor is now in possession of 0.27 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.41% having worth around $0.21 million. Moreover, Kepos Capital LP increased its share by 50000.0 to have a control over 50000.0 shares. And Warberg Asset Management LLC raised its holdings to 26000.0 shares by acquiring 27000.0 shares or 0.86% of the stake.
Bone Biologics Corp (BBLG) concluded trading on 11/15/23 at a closing price of $0.54, with 3.65 million shares of worth about $1.97 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -89.20% during that period and on Wednesday the price saw a gain of about 8.62%. Currently the company’s common shares owned by public are about 3.13M shares, out of which, 2.74M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the BBLG stock and their offered price forecasts bring an average price target of $7.50. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.50 and could fall to a lowest price of $7.50. The stock’s current price level is 98.56% above of average price target set by the analysts, while a rise to estimated low would result in gain of 92.8% for the stock. However, touching the estimated high of $7.50 would mean a gain of 92.8% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 1 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 1 selling transactions, insiders dumped 500,137 shares.
The company recently came buying 15816.0 shares which brought its stake up to 0.51% of the company’s outstanding shares.
However, the stock later moved at a day high price of 0.5431, or with a gain of 8.62%. Stock saw a price change of 2.70% in past 5 days and over the past one month there was a price change of -12.40%. Year-to-date (YTD), BBLG shares are showing a performance of -91.37% which decreased to -93.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.47 but also hit the highest price of $13.20 during that period. The average intraday trading volume for Bone Biologics Corp shares is 266.34K. The stock is currently trading 0.21% above its 20-day simple moving average (SMA20), while that difference is down -11.58% for SMA50 and it goes to -86.35% lower than SMA200.
Walleye Capital LLC acquired 0.29 million shares of Bone Biologics Corp having value of about $0.21 million. Data submitted at the U.S SEC by Walleye Capital LLC revealed that the firm now holds 0.27 million shares in the company valued at close to $144789.12, or have control over 997.80% stake in the company. Bone Biologics Corp (NASDAQ: BBLG) currently have 3.13M outstanding shares and institutions hold larger chunk of about 13.98% of that. Holding of mutual funds in the company is about 1.03% while other institutional holders and individual stake holders have control over 14.90% and 0.51% of the stake respectively.
The stock has a current market capitalization of $1.70M. It has posted earnings per share of -$10.05 in the same period. It has Quick Ratio of 1.69 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BBLG, volatility over the week remained 8.48% while standing at 7.57% over the month.
Stock’s fiscal year EPS is expected to drop by -60.30% while it is estimated to decrease by -15.48% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Bone Biologics Corp (BBLG)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
